Given that ∼48% of ACS patients showed a blood glucose greater than 8 mM (3, 17), indicating some degree of stress-hyperglycaemia, we suggest that selective PKCα/β inhibitors should be investigated as a potential cardioprotective alternative to aggressive lowering of blood glucose. Here, PRKCA is linked to Hyperglycemia.